March 18, 2022
Ignis Therapeutics and STADA’s Britannia Pharmaceuticals Team up for Apomorphine Subcutaneous Injection in China
Ignis Therapeutics and STADA’s Britannia Pharmaceuticals Ltd. affiliate have jointly announced that two companies have signed an exclusive licensing agreement under which Ignis Therapeutics will develop and commercialize subcutaneous apomorphine for Parkinson’s disease in mainland China, Hong Kong and Macau.